c-erbB2 过表达对转移性胃癌患者的预后意义。
Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer.
机构信息
Department of Medical Oncology, Uludag University Medical School, Bursa 16059, Turkey.
出版信息
Clin Transl Oncol. 2013 Apr;15(4):307-12. doi: 10.1007/s12094-012-0921-0. Epub 2012 Aug 22.
BACKGROUND
Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer.
METHODS
Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures.
RESULTS
c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in >10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 ± 1.03 months, whereas the mean TTP was 8.28 ± 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 ± 1.63 vs. 8.22 ± 0.88 months, respectively, p < 0.05) and TTP (10.72 ± 1.81 vs. 6.11 ± 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05).
CONCLUSION
Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer.
背景
编码受体酪氨酸激酶的基因 c-erbB2 的过度表达与几种实体瘤的预后和治疗反应有关。本研究旨在测试 c-erb-B2 过度表达是否与转移性胃癌患者的预后相关。
方法
在 2005 年至 2010 年间，对 46 例转移性胃癌患者进行了 c-erb-B2 过度表达的免疫组织化学评估。总生存期（OS）和无进展生存期（TTP）作为主要观察指标。
结果
c-erbB2 在 19 例（41.3%）病例中过度表达，8 例（17.4%）患者的 c-erbB2 评分为 3+（观察到>10%的肿瘤细胞存在强烈完整膜染色）。c-erbB2 表达与研究参与者的临床病理特征无关。平均 OS 为 11.48±1.03 个月，平均 TTP 为 8.28±0.8 个月。与评分为 2+或更低的患者（n=38）相比，评分为 3+的患者（n=8）的 OS（分别为 15.55±1.63 个月和 8.22±0.88 个月，p<0.05）和 TTP（分别为 10.72±1.81 个月和 6.11±0.61 个月，p<0.05）均显著降低。在考虑到潜在混杂因素后，Cox 回归分析发现 c-erbB2 评分为 3+是 OS（危险比=1.9；95%置信区间=1.1-3.7，p<0.05）和 TTP（危险比=1.8；95%置信区间=1.1-4.1，p<0.05）的独立预测因子。
结论
我们的结果表明，c-erbB-2 过度表达可能对转移性胃癌患者的预后具有预测意义。
Zotero 插件